卡纳单抗
 | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | IL-1β |
| 临床资料 | |
| 商品名 | Ilaris |
| 其他名称 | ACZ885, ACZ-885 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622024 |
| 核准状况 | |
| 怀孕分级 |
|
| 给药途径 | 静脉注射, 皮下注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 914613-48-2  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化学信息 | |
| 化学式 | C6452H9958N1722O2010S42 |
| 摩尔质量 | 145,157.20 g·mol−1 |
卡纳单抗（INN：Canakinumab）用于治疗周期性发热综合征、痛风和史迪尔氏病[4]。周期性发热症候群包括冷吡啉相关周期性症候群（Cryopyrin-associated periodic syndrome，CAPS）、Familial Mediterranean fever（Familial Mediterranean fever，FMF）、肿瘤坏死因子受体相关周期性症候群（Tumour necrosis factor receptor associated periodic syndrome，TRAPS）和甲羟戊酸激酶缺乏症（Mevalonate kinase deficiency，HIDS/MKD）[4]。透过皮下注射给药[4]。
常见的副作用包括鼻咽感染、腹痛、恶心和注射部位反应[4] [5]。其他副作用包括可能感染[5]。使用此药物期间不应接种活疫苗[5]。它是一种单克隆抗体，可结合并阻断介白素1β [4]。
卡纳单抗于 2009 年在美国和欧洲取得医疗使用许可[6] [4]。
参考文献
[编辑]- ^ Rondeau JM, Ramage P, Zurini M, Gram H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. mAbs. 2015, 7 (6): 1151–1160. PMC 4966334
. PMID 26284424. doi:10.1080/19420862.2015.1081323.
- ^ Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution. DailyMed. 14 September 2019 [16 June 2020].
- ^ Ilaris EPAR. European Medicines Agency (EMA). 17 September 2018 [16 June 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 4.0 4.1 4.2 4.3 4.4 4.5 Ilaris. [29 December 2021]. （原始内容存档于11 June 2020）.
- ^ 5.0 5.1 5.2 Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution. DailyMed. 14 September 2019 [16 June 2020]. （原始内容存档于4 August 2020）.
- ^ Canakinumab Monograph for Professionals. Drugs.com. [29 December 2021]. （原始内容存档于4 July 2018） （英语）.
External links
[编辑]- Canakinumab. National Cancer Institute.
